Article

Quality of vision improves with wavefront-guided system

Barcelona, Spain—The Zyoptix system (Bausch & Lomb) for wavefront-guided ablation is as effective as the conventional Planoscan (Bausch & Lomb) LASIK procedure in the correction of low to moderate myopia. Zyoptix, however, is advantageous because it induces less total, higher-order, and third-order aberrations. In addition, the quality of vision under low illumination and with low-contrast objects is better than that achieved with Planoscan, according to Jorge Castanera, MD, and Carlos Rios, OC.

The investigators conducted a study at the Instituto de OftalmologíCastanera, Barcelona, Spain, in which they evaluated the efficacy and safety of the two systems. The 25 study patients were treated in one eye with the Zyoptix system with Zylink 2.33 software and in the other eye with Planoscan.

"We used very strict inclusion criteria so that both eyes were equal. We then selected randomly one eye for Zyoptix treatment and the contralateral eye served as control and was treated with Planoscan," explained Dr. Castanera, medical director, Instituto de Oftalmología Castanera.

In the eyes treated with Planoscan, the mean spherical equivalent was -4.14 ± 1.91 D (range, -1.13 to -9 D), the sphere was -3.90 ± 1.82 D (range, -1 to -8.5 D), and the cylinder was -0.48 ± 0.44 D (range, 0 to -1.5 D).

In the eyes treated with Zyoptix, the mean spherical equivalent was -4.15 ± 1.77 D (range, -1.5 to -9 D), the sphere was -3.85 ± 1.66 D (range, -1.5 to -8.5 D), and the cylinder was -0.59 ± 0.44 D (range, 0 to -1.75 D). Dr. Castanera reported that the results were analyzed for up to 3 months after the treatment and that there was no difference in the refractive results or in the uncorrected visual acuity between the two groups.

The spherical equivalent was very stable and similar in the two groups at 1 week, 1 month, and 3 months after the surgery, 0.13, -0.01, and -0.09 D, respectively, in the eyes treated with Zyoptix and -0.24, -0.08, and -0.18 D in the eyes treated with Planoscan. The uncorrected visual acuity levels in LogMAR units at 1 week, 1 month, and 3 months in the eyes treated with Zyoptix were -0.08, -0.1, and -0.09, respectively. In the eyes treated with Planoscan the respective values were 0.24, -0.08, and -0.18.

Dr. Castanera also reported that the eyes treated with Zyoptix had significantly less total and higher-order aberrations and less third-order aberrations. Both comparisons reached statistical significance at the 3-month time point (p = 0.002 for total higher-order aberrations and p = 0.0003 for third-order aberrations).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
ASCRS 2025: Eva Kim, MD, discusses implantable collamer lenses and high myopia.
Abby Markward, MBA, and Hattie Hayes, editor of Ophthalmology Times Europe, discuss the ASCRS and ASOA meetings
Abby Markward discusses the ASCRS Foundation and the ASCRS Annual Meeting
(Image credit: Ophthalmology Times) Inside ASCRS 2025: Francis S. Mah, MD, takes the helm with a vision for research, education, and advocacy
(Image credit: Ophthalmology Times) NeuroOp Guru: Cranial nerve six palsy with chemosis is a critical clue to cavernous carotid fistula
© 2025 MJH Life Sciences

All rights reserved.